The debate mentioned tau PTM targeting but did not identify which modifications are both disease-specific and accessible for therapeutic intervention. This knowledge gap limits the development of PTM-based selective targeting approaches.
Source: Debate session sess_SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd (Analysis: SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd)
Proteolytic cleavage at Asp-421 by caspase-2/3 produces aggregation-competent tau C-terminal fragments that are detected in human AD brain but absent in age-matched cognitively normal controls.
No AI visual card yet
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
6 citations6 with PMID5 mediumValidation: 42%5 supporting / 1 opposing
✓For(5)
5
No opposing evidence
(1)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
2
MECH 4CLIN 0GENE 2EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
NRN1 may Modulate Tau Phosphorylation and Neuronal…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-12 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Mechanistically-Specific Hypotheses: Disease-Specific and Therapeutically-Accessible Tau PTMs
Title: K280 acetylation defines pathogenic tau conformers
Mechanism: p300/CBP-mediated acetylation at K280 (within the microtubule-binding repeat domain) converts tau into a aggregation-competent state by disrupting microtubule binding while simultaneously creating a β-sheet nucleation interface. This acetylated form recruits unmodified tau into oligomers, functioning as a dominant-
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Skeptic's Evaluation of Mechanistically-Specific Tau PTM Hypotheses
Hypothesis 1: K280 Acetylation as Aggregation Nucleation Site
Strongest Specific Weakness
Mechanistic claim exceeds structural evidence. The assertion that K280 acetylation creates a "β-sheet nucleation interface" implies a defined conformational change, yet no atomic-resolution structure of acetylated tau exists showing how this modification templated aggregation. The proposed mechanism conflates correlation (K280 acetylation correlates with disease) with causation (acetylation drives nucleation). W
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Domain Expert Assessment: Tau PTM Translational Potential
1. Prioritized Hypotheses by Translational Potential
Hypothesis A (Highest Priority): Truncation at Asp-421 as a Disease-Specific, Amplifiable Seed
Why this rises to top translational candidate:
| Dimension | Assessment | |-----------|------------| | Disease Specificity | C-terminal truncation at D421 is detected in human AD brain but not age-matched controls with normal cognition (Zhao et al., 2016; PMID: 26797856). Unlike phosphorylation (ubiquitous in aging), this cleavage event appears restricted to patho
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{ "ranked_hypotheses": [ { "rank": 1, "title": "Caspase-2/3-mediated D421 truncation generates disease-specific aggregation seeds", "mechanism": "Proteolytic cleavage at Asp-421 by caspase-2/3 produces aggregation-competent tau C-terminal fragments that are detected in human AD brain but absent in age-matched cognitively normal controls.", "target_gene": "CASP2/CASP3", "confidence_score": 0.75, "novelty_score": 0.55, "feasibility_score": 0.65, "impact_score": 0.85, "composite_score": 0.73, "testable_prediction": "Caspase-2 kno
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
💬 Discussion
Loading comments...
No DepMap CRISPR Chronos data found for CASP2/CASP3.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
IF human post-mortem prefrontal cortex (BA9/BA46) tissue from clinically confirmed AD cases (Braak stage V-VI, NIA-AA criteria) is compared to age-matched cognitively normal controls, THEN D421-truncated tau fragment concentration will be ≥3-fold higher in AD cases with measurable Thioflavin-S positive inclusions, detectable within 48h of tissue processing.
pendingconf: 0.82
Expected outcome: ≥3-fold higher concentration of D421 tau fragments in AD vs control tissue (normalized to total tau)
Falsified by: Equal or lower D421 fragment levels in AD cases compared to controls (any fold-change <1.0 or p>0.05) would indicate D421 truncation is not disease-specific
Method: Post-mortem prefrontal cortex homogenates from NIH-funded Alzheimer's Disease Research Center cohort (n≥30 AD, n≥30 controls, matched for age ±5 years, PMI <6h), analyzed by ELISA with C-terminal tau antibody (residues 404-441) and validated by targeted mass spectrometry
IF caspase-2/3 activity is pharmacologically inhibited (using z-VDVAD-fmk or CASP2 siRNA) in iPSC-derived neurons from AD patients carrying MAPT mutations, THEN levels of tau fragments ending at Asp-421 will decrease by ≥50% compared to vehicle-treated controls within 72 hours, with corresponding reduction in Sarkowsky-positive aggregates.
pendingconf: 0.75
Expected outcome: ≥50% reduction in tau D421 fragments and ≥30% reduction in Sarkowsky-positive aggregate area per cell
Falsified by: No statistically significant reduction in D421 tau fragments (p>0.05) or increased aggregation burden following caspase-2/3 inhibition would disprove the causal link between caspase activity and D421 truncation
Method: iPSC-derived cortical neurons from AD patients with MAPT mutations (e.g., P301L), treated with 20μM z-VDVAD-fmk or CASP2-targeting siRNA, analyzed by western blot with D421-specific antibody and immunofluorescence at 72h post-treatment (n≥3 biological replicates)